Evidence map›Paper›PMID 34463674›Full record

ArticlePathologica2021

Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.

Antonio Marchetti, Mattia Barbareschi, Massimo Barberis, Simonetta Buglioni, Fiamma Buttitta, Matteo Fassan, Gabriella Fontanini, Caterina Marchiò, Mauro Papotti, Giancarlo Pruneri and 7 more

Abstract read
In one paragraph

Article in Pathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pathologica · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Antonio MarchettiLaboratory of Molecular Diagnostics, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, Italy.
Mattia BarbareschiDepartment of Pathology, Santa Chiara Hospital, Trento, Italy.
Massimo BarberisDivision of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Lombardy, Italy.
Simonetta BuglioniDepartment of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Fiamma ButtittaLaboratory of Molecular Diagnostics, Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, Italy.
Matteo FassanUnit of Surgical Pathology, Department of Medicine (DIMED), University of Padua.
Gabriella FontaniniDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.
Caterina MarchiòPathology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy.
Mauro PapottiPathology Unit, Department of Oncology, Città Della Salute e della Scienza Hospital, University of Turin, Turin, Italy.
Giancarlo PruneriDepartment of Pathology and Laboratory Medicine, IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Aldo ScarpaDepartment of Diagnostics and Public Health, Section of Pathology, and ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
Giorgio StantaDSM - Department of Medical Sciences, University of Trieste, Trieste, Italy.
Giovanni TalliniDepartment of Medicine (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, DIMES), University of Bologna, Italy.
Giancarlo TronconeDivision of Pathology, Department of Public Health, University of Naples Federico II, Naples, Italy.
Silvio Marco VeroneseMolecular Pathology Unit, Niguarda Hospital, Milan, Italy.
Mauro TruiniPathological Anatomy Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Anna SapinoDepartment of Surgical, Medical and Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next Generation Sequencing (NGS) is increasingly used in diagnostic centers for the assessment of genomic alterations to select patients for precision oncology. The Italian Society of Anatomic Pathology and Diagnostic Cytopathology (SIAPEC) through the Molecular Pathology and Predictive Medicine Study Group (PMMP) has been following the progressive development of centers that have adopted NGS technology in diagnostics over time. In July 2017, a study network on massive parallel sequencing was activated in Italy and recognized as the NGS SIAPeC National Network by the SIAPeC Scientific Society Board. Since then, activities have been implemented within the network that provide for alignment of laboratories through diagnostic concordance analysis and monitoring of centers adhering to the Network. Recently, considering the growing need for extended genomic analyses, the PMMP distributed a national survey to assess activities related to the use of genomic diagnostics in oncology within the NGS SIAPEC National Network. Thirty centers participated in the survey. Eighty percent of the centers are laboratories within Pathology Departments. The distribution of laboratories in the country, the diagnostic laboratory/population ratio, the staff dedicated, the type and number of sequencing and mechatronics platforms available, the genomic panels utilized, and the type and number of diagnostic tests carried out in the last year in each center, are reported. The centers were also asked whether they participated in a multidisciplinary Molecular Tumor Board (MTB) for management of patients. Thirty percent of the centers had a MTB that was ratified by regional decree. The professionals most frequently involved in the core team of the MTB are the pathologist, oncologist, molecular biologist, geneticist, pharmacologist, and bioinformatician. The data from this survey indicate that NGS diagnostics in Italy is still heterogeneous in terms of geographical distribution and the characteristics of laboratories and diagnostic test performed. The implementation of activities that favors harmonization, the logistics and the convergence of biological material in reference centers for molecular analyses is a priority for the development of a functional laboratory network.

Indexed as

NeoplasmsHigh-Throughput Nucleotide SequencingHumansItalyPathology, MolecularPrecision MedicineMolecular PathologyMolecular Tumor Board (MTB)Next generation Sequencing (NGS)

Identifiers

PMID34463674
PMCPMC8488986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.